Rouen Brockmann

Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development

B. Love, Ismaeel Yunusa, Rouen Brockmann, 2023, Lancet regional health. Americas.